ATE402253T1 - Humane adulte astrozyten, sowie deren herstellung und verwendung - Google Patents

Humane adulte astrozyten, sowie deren herstellung und verwendung

Info

Publication number
ATE402253T1
ATE402253T1 AT00901857T AT00901857T ATE402253T1 AT E402253 T1 ATE402253 T1 AT E402253T1 AT 00901857 T AT00901857 T AT 00901857T AT 00901857 T AT00901857 T AT 00901857T AT E402253 T1 ATE402253 T1 AT E402253T1
Authority
AT
Austria
Prior art keywords
human adult
production
astrocytes
adult astrocytes
trauma
Prior art date
Application number
AT00901857T
Other languages
English (en)
Inventor
Jean-Luc Ridet
Jacques Mallet
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE402253T1 publication Critical patent/ATE402253T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
AT00901857T 1999-01-05 2000-01-05 Humane adulte astrozyten, sowie deren herstellung und verwendung ATE402253T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11475899P 1999-01-05 1999-01-05

Publications (1)

Publication Number Publication Date
ATE402253T1 true ATE402253T1 (de) 2008-08-15

Family

ID=22357256

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00901857T ATE402253T1 (de) 1999-01-05 2000-01-05 Humane adulte astrozyten, sowie deren herstellung und verwendung

Country Status (12)

Country Link
US (1) US6943016B1 (de)
EP (1) EP1141241B1 (de)
JP (1) JP2003524391A (de)
KR (1) KR20020013487A (de)
CN (1) CN1340098A (de)
AT (1) ATE402253T1 (de)
AU (1) AU2315100A (de)
CA (1) CA2355967A1 (de)
DE (1) DE60039579D1 (de)
HU (1) HUP0105066A2 (de)
IL (1) IL143382A0 (de)
WO (1) WO2000040699A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006506970A (ja) 2002-07-12 2006-03-02 ユニバーシティ オブ ワシントン 神経細胞の延長されたインビトロ培養のための方法および系
JP4670363B2 (ja) * 2005-01-21 2011-04-13 住友ベークライト株式会社 ミクログリア細胞の輸送方法
CN1952662B (zh) * 2005-08-26 2011-05-18 中国科学院上海生命科学研究院 星形胶质细胞磷酸化蛋白pea-15的应用
MY161818A (en) 2007-04-20 2017-05-15 Acucela Inc Styrenyl derivate compounds for treating ophthalmic diseases and disorders
NZ601866A (en) 2007-06-29 2013-12-20 Acucela Inc Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders
MY155320A (en) 2007-10-05 2015-09-30 Acucela Inc Alkoxy compounds for disease treatment
JP2015505536A (ja) 2012-01-20 2015-02-23 アクセラ インク． 疾患の処置のための置換された複素環化合物
CN105209428A (zh) 2013-03-12 2015-12-30 奥克塞拉有限公司 用于治疗眼科疾病和病症的取代的3-苯基丙胺衍生物
JP6906231B2 (ja) * 2015-09-29 2021-07-21 学校法人慶應義塾 アストロサイト様細胞及びその調製方法
CN113337469B (zh) * 2021-07-16 2023-03-24 广州市妇女儿童医疗中心 星形胶质细胞亚群及其分离纯化方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202120A (en) * 1987-09-11 1993-04-13 Case Western Reserve University Methods of reducing glial scar formation and promoting axon and blood vessel growth and/or regeneration through the use of activated immature astrocytes
US5650148A (en) * 1988-12-15 1997-07-22 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage of the central nervous system
US5750376A (en) * 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
WO1993007280A1 (en) * 1991-10-04 1993-04-15 The Government Of The United States Of America As Represented By The Department Of Health And Human Services Astrocyte-specific transcription of human genes
WO1994001135A1 (en) * 1992-07-06 1994-01-20 The Research Foundation Of State University Of New York Method of producing genetically modified astrocytes and uses thereof

Also Published As

Publication number Publication date
KR20020013487A (ko) 2002-02-20
CN1340098A (zh) 2002-03-13
WO2000040699A2 (en) 2000-07-13
DE60039579D1 (de) 2008-09-04
IL143382A0 (en) 2002-04-21
EP1141241A2 (de) 2001-10-10
US6943016B1 (en) 2005-09-13
AU2315100A (en) 2000-07-24
EP1141241B1 (de) 2008-07-23
JP2003524391A (ja) 2003-08-19
WO2000040699A3 (en) 2000-11-02
HUP0105066A2 (hu) 2002-04-29
CA2355967A1 (en) 2000-07-13

Similar Documents

Publication Publication Date Title
DK0822829T3 (da) Anvendelse af glial neurotrofisk faktor (GDNF) til behandling af høreforstyrrelser
ATE97809T1 (de) Verwendung von 5-methyltetrahydrofolsaeure, 5formyltetrahydrofolsaeure sowie deren pharmazeutisch geeigneten salzen zur herstellung von arzneimitteln mit gesteuerter freigabe und wirksam in der therapie organisch mentaler stoerungen sowie die entsprechenden arzneimittel.
ATE412415T1 (de) Inhibitoren der phosphodiesterase der zyklischen nucleotiden, mit einer benzodiazepinischen struktur, und deren verwendung in therapie
SG158731A1 (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
DE69810635T2 (de) Verwendung von neurturin protein zur vorbeugung und behandlung von gehörverlust
ATE209492T1 (de) Verwendung von 1,2,4-triazolo(1,5-c)pyrimidine heterocyclischen analogen zur herstellung von arzneimitteln zur behandlung von zerebrovascularen störungen
TR200102170T2 (tr) Psikiyatrik ve nörolojik bozukluklar için yüksek ölçüde saflaştırılmış etil EPA ve diğer EPA türevleri.
ATE492279T1 (de) Bupropinmetaboliten zur behandlung von dementia und anderen zerebrovasckulären erkrankungen
HUT77927A (hu) Nebivolol-származékok alkalmazása antiatherogén hatású gyógyászati készítmények előállítására és e vegyületeket tartalmazó kombinációs gyógyászati készítmények
DE69510928D1 (de) Heterocyclische verbindungen, ihre herstellung und verwendung
ATE342964T1 (de) Rekombinante alpha-l-iduronisase, deren herstellungs- und aufreinigungsverfahren, und behandlung von durch diese hervorgerufene mangelerkrankungen
PL313716A1 (en) Tetrachloropyridino-(or 4-hydroxypiperidino) alkyloazoles exhibiting activity in respect to sigma and/or 5ht1a receptor
ATE322252T1 (de) Verfahren zur herstellung und sammlung von kristallinen partikeln
DE69331605D1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
DE69703617D1 (de) Verwendung von optisch reines (+) norcisapride zur behandlung von erbrechen und zns-störungen
ATE402253T1 (de) Humane adulte astrozyten, sowie deren herstellung und verwendung
ATE307203T1 (de) Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
ATE231849T1 (de) Cyclopentabenzofuran-derivate und ihre verwendung
BG103687A (en) Atropisomers of 3-heteroaryl-4(3h)-quinazolinones for the treatment of neurodegenerative processes and conditions related to the central nervous system
ATE169500T1 (de) Verwendung von guanosin zur herstellung von arzneimitteln zur behandlung von zerebralen funktionsstörungen
WO2004043373A3 (en) Precursor n-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme
PL310950A1 (en) Novel imidazole quinoxalinones, method of obtaining them and their application
ATE261724T1 (de) Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen
ATE334680T1 (de) 4-aminopiperidin-derivate, verfahren zur herstellung und ihre verwendung als arzneimittel
ATE357914T1 (de) Verwendung von 4-aminopyridin zur behandlung von peripheren neuropathien

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties